MedTrace Logo

Study to Evaluate the Safety and Tolerability of EP0042

NCT04581512 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2025-10-14

No results posted yet for this study

Summary

A research study looking at a new treatment for patients with advanced cancer, to investigate different doses of the experimental study drug, EP0042, in order to determine a dose, which is safe, well-tolerated and likely to be effective in treating AML (acute myeloid leukaemia).

Conditions

Interventions

DRUG

EP0042

EP0042 Oral 20 mg 50 mg capsules

DRUG

Venetoclax

Venetoclax

DRUG

Azacitidine (AZA)

Azacitidine

Sponsors & Collaborators

  • Ellipses Pharma

    lead INDUSTRY

Principal Investigators

  • David Taussig · The Royal Marsden, UK

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-02
Primary Completion
2025-10-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • Australia
  • Netherlands
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04581512 on ClinicalTrials.gov